EMA Authorised: Herceptin (trastuzumab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Herceptin (trastuzumab) for stomach neoplasms and breast neoplasms. The marketing authorization holder is Roche Registration GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Stomach Neoplasms

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Roche Registration GmbH. Decision date: 24/11/2025